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Introduction: The purpose of this study was to evaluate the clinical efficacy in our daily 
practice, outside clinical trials, of cetuximab plus radiotherapy in a majority of treatment-naive 
patients with locoregionally advanced head and neck squamous cell carcinomas.
Methods: A retrospective study was performed to evaluate outcomes in patients who were 
treated definitively with cetuximab and radiotherapy (ExRT). Patients with stage III or IV, 
nonmetastatic, measurable squamous cell carcinoma of the head and neck (SCCHN) were 
eligible.
Results: There were 18 males and two females. The median age was 61 years (range from 
49 to 87 years old). Concurrent radiotherapy and cetuximab was used, in first line, in 17 patients 
with locally advanced disease; two patients with recurrent SCCHN, who were intolerant of 
  Cisplatin-based regimens, were treated with radiotherapy combined with weekly cetuximab; and 
1 patient received cetuximab and radiotherapy postoperatively. The median time of response was 
10 months (range from 2 to 24 months). A partial response was observed in 11 cases; a complete 
response in nine cases. The occurrence of grade 2–3 skin toxicity was observed in 11 cases. 
Skin toxicity was clearly correlated with a better response and the duration of the response to 
the treatment. The use of cetuximab in combination with radiotherapy does not increase the 
side effects of radiotherapy. At the end of the follow-up, 17 patients died.
Conclusion: Cetuximab, with its highly targeted mechanism of action and synergistic   activity 
with current treatment modalities, is a valuable treatment option in head and neck patients. 
The effect of the epidermal growth factor receptor antagonist occurs without any change in the 
pattern and the severity of toxicity usually associated with head and neck   radiation.   Cetuximab 
seems not to provide the most benefit for patients with oropharyngeal cancers but will in 
patients with T4 tumors. However, the median duration of local control was less as described 
in the clinical trials.
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Introduction
As 90% of all cases of squamous cell cancer of the head and neck show expression of 
epidermal growth factor receptor (EGFR), there is a strong rationale supporting EGFR 
targeting in this malignancy. This rationale is further strengthened by the fact that 
EGFR overexpression is associated with worse prognosis1,2 molecule consists of an N 
terminal, extracellular, ligand-binding domain; a hydrophobic transmembrane domain; 
and a C-terminal intracellular domain with tyrosine kinase activity. The EGFR can be 
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EGF, which bind to the extracellular domain of the receptor. 
This ligand binding results in EGFR dimerization and activa-
tion of the tyrosine kinase domains present on each receptor. 
This kinase activation results in cross-phosporylation of 
tyrosine residues on each member of the receptor repair and 
initiates the formation of signalling complexes in the cyto-
plasm, which can translocate to the cell nucleus and activate 
gene transcription. This editing of gene transcription eventu-
ally result in the induction of several cellular responses such 
as cell proliferation. Ultimately receptor ligand complexes 
are internalized and the signal is terminated. Nowadays there 
are two EGFR targeting strategies used in clinical practice: 
monoclonal antibodies directed at the extracellular domain 
of the receptor and small molecule, and ATP tyrosine kinase 
inhibitors.4,5 The use of both modalities in the treatment 
of SCCHN is   currently under investigation. Thus far, the 
  monoclonal EGFR antibody cetuximab has been studied 
in detail. Cetuximab is a human-murine chimeric immuno-
globulin G1 monoclonal antibody that competitively binds to 
the extracellular domain of the EGFR preventing activation 
of the receptor by endogenous ligands. The antibody-receptor 
complex is internalized and degraded resulting in a down 
regulation of the EGFR expression.
Cetuximab has been tested in metastatic/and or recurrent 
SCCHN both in first-line treatment in combination with 
platinum-based chemotherapy and as second-line after failure 
of platinum-based chemotherapy. Cetuximab has also been 
tested in association with radiation as definitive treatment 
for locoregionally advanced SCCHN.
The purpose of this study was to evaluate the clinical effi-
cacy in our daily practice, outside clinical trials, of cetuximab 
plus radiotherapy in a majority of treatment-naive patients 
with locoregionally advanced head and neck squamous cell 
carcinomas.
Methods
A retrospective study was performed to evaluate outcomes 
in patients who were treated definitively with cetuximab 
and radiotherapy (ExRT). Only those patients judged to be 
medically suitable for definitive radiotherapy and who had 
a Karnofsky performance score of at least 60 with normal 
hematopoietic, hepatic, and renal function were eligible. 
Cetuximab and concurrent radiotherapy was used to treat 
20 consecutive patients with squamous cell carcinoma of 
the head and neck (SCCHN), all of whom had tumors of the 
oral cavity, oropharynx, hypopharynx, or larynx. Patients 
with stage III or IV , nonmetastatic, measurable SCCHN were 
eligible. The prognostic significance of human papillomavirus 
(HPV) status has only become clear in recent studies, and 
therefore no HPV testing was done systematically. Intravenous 
administration of cetuximab was initiated one week before 
radiotherapy at a loading dose of 400 mg/m2 followed by 
weekly administration of 250 mg/m2 for the duration of con-
ventionally fractionated radiotherapy (70 Gy in 35 fractions 
of 2 Gy, 5 fractions/week for 7 weeks). Tumor responses were 
assessed by computed tomography (CT) or magnet resonance 
imaging (MRI) at baseline and at 6-week intervals after the 
start of treatment until disease progression.
Results
There were 18 male and 2 female patients. The median age 
was 61 years (range from 49 to 87-years-old). Nine patients 
presented an oropharyngeal tumor; seven patients had a 
hypopharyngeal tumor. The tumor was located at the oral 
cavity in two cases, and in the larynx in two cases. Seventeen 
patients were stage IV; three patients were stage III.
Concurrent radiotherapy and cetuximab was used as first line 
treatment in 17 patients with locally advanced disease; two patients 
with recurrent SCCHN and who were intolerant of cisplatin-based 
regimens were treated with radiotherapy   combined with weekly 
cetuximab; and 1 patient received cetuximab and radiotherapy 
postoperatively. The median time of response was 10 months 
(range from 2 to 24 months). A partial response was observed 
in 11 cases; a complete response in nine cases. Among the nine 
patients with oropharyngeal tumor, the response was partial in 
six cases and complete in three cases. Among the patients with 
hypopharyngeal tumor, the response was partial in three cases 
and complete in four cases. After a follow-up of 33 months, the 
median survival time was 14 months.
The occurrence of grade 2–4 skin toxicity was observed 
in 11 cases. Skin toxicity was clearly correlated with a better 
response and the duration of the response to the treatment. 
The use of cetuximab in combination with radiotherapy does 
not increase the side effects of radiotherapy.
The cetuximab-induced rash began within 35 days of the 
initiation of treatment in 95% of patients. Of the patients who 
received cetuximab, 94% received at least seven doses, and 
90% received at least 1800 mg/m2. There was no association 
between cumulative dose and rash.
Patients with a prominent rash had longer survival com-
pared with those with mild rash.
At the end of the follow-up, 17 patients died.
Discussion
It has been shown that cetuximab and radiation have a 
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  xenografts.1 Hence the rationale for combination radiotherapy 
with cetuximab in SCCHN is clearly present.2,3,4
In an initial study, cetuximab showed encouraging 
activity in patients with locally advanced SCCHN. In this 
phase I trial,5 16 patients with advanced SCCHN received 
treatment with cetuximab combined with either conventional 
or hyperfractionated radiotherapy. There was an impressive 
100% response rate (13 complete and two partial responses) 
and interestingly, both treatments were generally well 
tolerated.
Furthermore, reported results showed better survival 
and locoregional disease control associated with cetuximab 
plus radiotherapy in patients with SCCHN, relative to radio-
therapy alone, and these differences were not associated 
with reduced quality of life or increased radiation-induced 
mucositis or dysphagia. Indeed, in a multinational random-
ized study,6 424 patients with locoregionally advanced 
SCCHN were randomized to receive radiotherapy alone or 
radiotherapy combined with weekly cetuximab. Patients with 
stage III or IV, nonmetastatic, measurable squamous cell 
carcinoma of the oropharynx, hypopharynx or larynx were 
eligible. The primary endpoint was the duration of control 
of locoregional disease. Secondary endpoints were overall 
survival, progression free survival, the response rate, and 
safety. The median duration of locoregional control was 
24.4 months with combined therapy and 14.9 months with 
radiotherapy alone (P = 0.005). The one-, two-, and three-
year rates of locoregional controls achieved with radiotherapy 
plus cetuximab (63%, 50%, 47%) were significantly higher 
than those achieved with radiotherapy alone (55%, 41%, 
34%, respectively; P , 0.01 for the comparison at three 
years). With a median follow up of 54 months the median 
survival time was 49 months among patients treated with 
combined therapy and 29.3 months among those given 
radiotherapy alone (P = 0.03).
In our study, the median time of response was 10 months 
(range from 2 to 24 months). A partial response was observed 
in 11 cases; a complete response in nine cases. After a 
follow-up of 33 months, the median survival time was 14 
months.
An update analysis was done to assess additional 5-year 
overall survival results.7 The long-term results corrobo-
rate the earlier findings that the addition of cetuximab to 
radiotherapy improved the survival of patients with SCCHN. 
There was a difference of about 9% in absolute survival for 
the addition of cetuximab to radiotherapy compared with 
radiotherapy alone (36.4% vs 45.6%). Additionally, the 
subgroup analyses showed that patients given cetuximab 
who developed prominent cetuximab-induced acneiform 
rash (grade 2–4) had better overall survival compared with 
patients given cetuximab who developed a mild or not rash 
(grade 0–1). In our study, also, patients who developed 
grade 2–4 rash had a better survival time than patients who 
developed no rash.
In their study,7 the overall survival benefit associated with 
the addition of cetuximab to radiotherapy relative to radio-
therapy alone is remarkably similar to that seen in the 3-year 
analysis (45% vs 55%), which supports the validity of 3-year 
survival as a surrogate for long term overall survival.
The development of acneiform rash is a toxicity that is 
frequently associated with cetuximab and not radiotherapy 
alone. The characteristic cetuximab-induced acneiform 
rash rises during treatment and generally resolves com-
pletely in the first weeks following the cessation of the 
treatment.8 Of the 208 patients who received cetuximab and 
had information regarding skin toxicity, 174 (84%) patients 
had rash and the incidence was similar to previous report 
of cetuximab alone.9 127 patients had prominent rash, the 
remaining 81 patients had mild rash or none. Patients with 
prominent rash had more than 2.5 times longer overall sur-
vival than did patients with mild rash.
Notably, cetuximab did not dramatically exacerbate the 
common toxic effects associated with radiotherapy of the 
head and neck, including mucositis, xerostomia, dysphagia, 
pain, weight loss, and performance status deterioration.10 
However, a few cases of severe skin reactions within the 
radiation field were reported.11 In our study, each case of 
severe skin reaction was strongly correlated with a complete 
response to the treatment. As in other tumors the occurrence 
of grade 2–4 skin toxicity in SCHNN patients treated with 
cetuximab is associated with better outcome.12–14 In our study, 
skin toxicity was clearly correlated with a better response and 
the duration of the response to the treatment.
Furthermore, cetuximab seems to provide the most benefit 
for patients with oropharyngeal tumors, T1–3 tumors, treat-
ment in the USA, concomitant boost, advanced nodal stage, 
and high Karnofosky Performance Scale. In our study, among 
the nine patients with an oropharyngeal tumor, a complete 
response was observed in only three cases, a partial response 
in six cases. Cetuximab seems to provide the most benefit 
for patient with T4 tumors. These subgroups represent small 
numbers of patients and therefore the results might represent 
spurious findings.
In conclusion, cetuximab, with its highly targeted mecha-
nism of action and synergistic activity with current treatment 
modalities, is a valuable treatment option in head and neck Cancer Management and Research
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patients. The effect of the EGFR antagonist occurs without 
any change in the pattern and the severity of toxicity usually 
associated with head and neck radiation. Cetuximab seems 
not to provide the most benefit for patients with oropharyn-
geal cancers but will in patients with T4 tumors. However, 
the median duration of local control was less as described 
in the clinical trials.
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